The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: Assessment with Technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography

Biological Psychiatry

Volumn 41, Issue 5, 1997, Pages 550-559

  Miller, Del D ^a   Rezai, Karim ^a   Alliger, Randall ^a   Andreasen, Nancy C ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

antipsychotics; relative regional cerebral blood flow; schizophrenia; Tc 99m HMPAO SPECT

Indexed keywords

CLOZAPINE; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NEUROLEPTIC AGENT; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BRAIN; BRAIN MAPPING; CEREBELLUM; CEREBRAL CORTEX; CHRONIC DISEASE; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MALE; ORGANOTECHNETIUM COMPOUNDS; OXIMES; PSYCHIATRIC STATUS RATING SCALES; REGIONAL BLOOD FLOW; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TECHNETIUM TC 99M EXAMETAZIME; THIOTHIXENE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRIFLUOPERAZINE;

EID: 0031105948     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00110-2     Document Type: Article

References (36)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Press.
2. Andreasen N (1982): Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39:784-788.
3. Andreasen N (1983): The Scale for the Assessment of Negative Symptoms (SANS), Iowa City, IA: University of Iowa.
4. Andreasen N (1984): The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa.
5. Andreasen N, Flaum M, Arndt S (1992a): The Comprehensive Assessment of Symptoms and History (CASH): An instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 49:615-623.
6. Andreasen N, Rezai K, Alliger R, et al (1992b): Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with Xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49:943-958.
7. Ariel R, Notestine R, Golden C, et al (1983): Regional cerebral blood flow in schizophrenia. Arch Gen Psychiatry 40:258-263.
8. Bartlett E, Wolkin A, Brodie J, LaSka E, Wolf A, Sanfilipo M (1991): Importance of pharmacologic control in PET studies: Effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res Neuroimaging 40:115-124.
9. Berman K, Zec R, Weinberger DR (1986): Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: II. Role of neuroleptic treatment, attention, and mental effort. Arch Gen Psychiatry 43:126-135.
10. Brodie J, Christman D, Fowler J (1984): Patterns of metabolic activity in the treatment of schizophrenia. Ann Neurol 15(suppl):S166-S169.
11. Buchsbaum M, Ingvar D, Kessler R, et al (1982): Cerebral glucography with positron tomography. Arch Gen Psychiatry 39:251-259.
12. Buchsbaum M, Wu J, DeLisi L, et al (1987): Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients. Biol Psychiatry 22:479-494.
13. Buchsbaum M, Potkin S, Marshall J, et al (1992a): Effects of clozapine and thiothixene on glucose metabolism rate in schizophrenia. Neuropsychopharmacology 6:115-163.
14. Buchsbaum M, Potkin S, Siegel B, et al (1992b): Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 49:966-974.
15. DeLisi L, Holcomb H, Cohen R, Pickar D, Carpenter W, Morihisa J (1985): Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 5:201-206.
16. Dousse M, Mamo H, Ponsin J, Tran Dinh Y (1988): Cerebral blood flow in schizophrenia. Exp Neurol 100:98-111.
17. Geraud G A-BM, Guell A, Bes A (1987): Reversibility of hemodynamic hypofrontality in schizophrenia. J Cereb Blood Flow Metab 7:9-12.
18. Gur R, Skolnick B, Gur R (1983): Brain function in psychiatric disorders: I. Regional cerebral blood flow in schizophrenia. Arch Gen Psychiatry 40:1250-1254.
19. Gur R, Gur R, Skolnick B, et al (1985): Brain function in psychiatric disorders: III. Regional cerebral blood flow in unmedicated schizophrenics. Arch Gen Psychiatry 42:329-334.
20. Gur R, Resnick S, Gur R, et al (1987): Regional brain function in schizophrenia: II. Repeated evaluation with positron emission tomography. Arch Gen Psychiatry 44:126-129.
21. Ingvar D, Franzen G (1974): Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 15:425-462.
22. Jibiki I, Matsuda H, Yamaguchi N, Kurokawa K, Hisada K (1990-1991): Acutely administered haloperidol-induced widespread reduction of regional cerebral blood flow observed from subtraction of brain imaging with single photon emission computed tomography using Technetium-99m hexamethyl-propyleneamine oxime. Neuropsychobiology 24: 125-128.
23. Levy A, Brodie J, Russell A, Volkow N, Laska E, Wolf A (1989): The metabolic centroid method for PET brain image analysis. J Cereb Blood Flow Metab 93:388-397.
24. Mathew R, Duncan G, Weinman M, Barr D (1982): Regional cerebral blood flow in schizophrenia. Arch Gen Psychiatry 39:1121-1124.
25. Mathew R, Wilson W, Tant S, Robinson L, Prakash R (1988): Abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia. Arch Gen Psychiatry 45: 542-549.
26. Miller D, Arndt S, Andreasen N (1993): Alogia, attentional impairment, and inappropriate affect: Their status in the dimensions of schizophrenia. Comp Psychiatry 34:221-226.
27. Perouka S, Snyder S (1980): Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518.
28. Richelson E, Nelson A (1984): Antagonism by neuroleptics of neurotransmitter receptors of normal brain in vitro. Eur J Pharmacol 103:197-204.
29. Sedvall G, Blomquist G, DePaulis T, et al (1985): PET Studies on Brain Energy Metabolism and Dopamine Receptors in Schizophrenic Patients and Monkeys. New York: Plenum Press.
30. Szechtman H, Nahmias C, Garnett S, et al (1988): Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 45:523-532.
31. Volkow N, Brodie J, Wolf A, Angrist B, Russell J, Cancro R (1986): Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry 49:1199-1202.
32. Warkentin S, Nilsson A, Risberg J, et al (1990): Regional cerebral blood flow in schizophrenia: Repeated studies during a psychotic episode. Psychiatry Res Neuroimaging 35:27-38.
33. Weinberger D, Berman K, Zee R (1986): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43:114-124.
34. Weinberger D, Berman K, Illowsky B (1988): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45:609-615.
35. Wik G, Wiesel F, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S (1989): Effects of sulpiride and chlorpromazine on regional glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology 97:309-318.
36. Wolkin A, Jaeger J, Brodie J, et al (1985): Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 142:564-571.